Pharmacokinetic characterization of controlled-release formulations

Area of Science:

• Pharmacokinetics and Drug Delivery
• Pharmaceutical Sciences
• Clinical Pharmacology

Background:

• Controlled-release (CR) formulations aim to enhance therapeutic outcomes through optimized drug delivery.
• Key clinical rationales include improving patient compliance, minimizing adverse effects, and maximizing efficacy.
• Current development practices necessitate a deeper understanding of CR formulation behavior.

Purpose of the Study:

• To establish a clinico-pharmacological framework for developing and evaluating controlled-release formulations.
• To propose advanced pharmacokinetic (PK) assessment methods for CR products.
• To define in vitro specifications linked to in vivo bioequivalence requirements.

Main Methods:

• Comparison of CR formulation PK profiles and dose regimens against immediate-release (IR) or other CR formulations under steady-state conditions.
• Evaluation using conventional PK parameters (AUC, tmax, Cmax) and novel metrics.
• Assessment of PK profiles under varying conditions: fed/fasted states, inter-day variability, and multiple dose levels.

Main Results:

• Suggested alternative PK characteristics: residual concentration, peak-through fluctuation, plateau time, statistical moments, in vivo input functions, and IV infusion mimicry.
• Emphasis on reproducing the steady-state PK profile across diverse physiological and dosing scenarios.
• Proposed linking in vitro dissolution specifications directly to in vivo bioequivalence needs for within-product consistency.

Conclusions:

• A robust clinico-pharmacological approach is essential for rational CR formulation development.
• Advanced PK metrics and comprehensive steady-state evaluations are crucial for characterizing CR performance.
• In vitro-in vivo correlation, particularly for within-product bioequivalence, should guide dissolution testing.